Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial

Jieping Lin, Chenhao Ding, Zicong Huang, Cai Zihong, Jia Li, Zhixiang Wang, Xiaofang Li, Xuan Zhou, Bailin He, Wenhao Zhong, Li Xuan, Qifa Liu, Yang Xu, Hongsheng Zhou

Blood (2024) 144 (Supplement 1): 839.

https://doi.org/10.1182/blood-2024-200513

Published: 2024

Journal Articles

IKZF1 Deletion Confers Resistance to CAR19 in r/r B-ALL Via CD19 Intron Retention

Cai Zihong, Baiwei Luo, Bailin He, Li Xuan, Qifa Liu, Hongsheng Zhou

Blood (2024) 144 (Supplement 1): 3412.

https://doi.org/10.1182/blood-2024-203362

Published: 2024

Journal Articles

Disruption of SOCS1 Promotes the Antitumor Activity of CD19-Specific CAR NK Cells Coexpressing IL-15

Hong Chen, Bailin He, Suzhen Zhong, Dongchao Huang, Shikai Deng, Qifa Liu, Chengyao Li, Lizhen Huang, Na Xu

Blood (2023) 142 (Supplement 1): 6829.

https://doi.org/10.1182/blood-2023-182516

Published: 2023

Journal Articles

CD19-Specific CAR NK Cells Coexpressing IL-21 Exhibit Superior Expansion and Antitumor Activity Against CD19-Postive Lymphoma

Bailin He, Hong Chen, Shikai Deng, Chengyao Li, Na Xu, Xiaoli Liu, Hongsheng Zhou, Qifa Liu

Blood (2023) 142 (Supplement 1): 6824.

https://doi.org/10.1182/blood-2023-178289

Published: 2023

Journal Articles

Efficacy and Safety of TLR2 Co-Stimulated CAR T Cells in CD19-Positive Lymphoid Malignancies with Central Nervous System Involvement

Bailin He, Hongsheng Zhou, Ren Lin, Zhixiang Wang, Na Xu, Qiang Wang, Jing Sun, Xiaoli Liu, Peng Li, Qifa Liu

Blood (2023) 142 (Supplement 1): 3484.

https://doi.org/10.1182/blood-2023-184492

Published: 2023

Journal Articles

Blockade of CD95/CD95L Death Signaling Enhances CAR T Cell Persistence and Antitumor Efficacy

Bailin He, PhD, Lei Wang, MD, Brigitte Neuber, Anita Schmitt, MD, Niclas Kneisel, PhD, Thomas Hoeger, PhD, Carsten Mueller-Tidow, MD, Michael Schmitt, MD, Susanne Hofmann, MD

Blood (2019) 134 (Supplement_1): 3226.

https://doi.org/10.1182/blood-2019-122833

Published: 2019

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial

IKZF1 Deletion Confers Resistance to CAR19 in r/r B-ALL Via CD19 Intron Retention

Disruption of SOCS1 Promotes the Antitumor Activity of CD19-Specific CAR NK Cells Coexpressing IL-15

CD19-Specific CAR NK Cells Coexpressing IL-21 Exhibit Superior Expansion and Antitumor Activity Against CD19-Postive Lymphoma

Efficacy and Safety of TLR2 Co-Stimulated CAR T Cells in CD19-Positive Lymphoid Malignancies with Central Nervous System Involvement

Blockade of CD95/CD95L Death Signaling Enhances CAR T Cell Persistence and Antitumor Efficacy

Email alerts

ASH Publications

American Society of Hematology

Update search

Tucidinostat Plus Pediatric-Inspired Chemotherapy As First-Line Therapy for Newly Diagnosed ETP-ALL/Lbl: An Open-Label, Single-Arm, Phase 2 Trial

IKZF1 Deletion Confers Resistance to CAR19 in r/r B-ALL Via CD19 Intron Retention

Disruption of SOCS1 Promotes the Antitumor Activity of CD19-Specific CAR NK Cells Coexpressing IL-15

CD19-Specific CAR NK Cells Coexpressing IL-21 Exhibit Superior Expansion and Antitumor Activity Against CD19-Postive Lymphoma

Efficacy and Safety of TLR2 Co-Stimulated CAR T Cells in CD19-Positive Lymphoid Malignancies with Central Nervous System Involvement

Blockade of CD95/CD95L Death Signaling Enhances CAR T Cell Persistence and Antitumor Efficacy

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only